Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Badanie Fedratinibu u Japończyków z DIPSS (Dynamic International Prognostic Scoring System) – pierwotne zwłóknienie szpiku (PMF) średniego lub wysokiego ryzyka, zwłóknienie szpiku poprzedzone czerwienicą prawdziwą (MF po PV) lub zwłóknienie szpiku poprzedzone nadpłytkowością samoistną (post-ET) MF)

8 listopada 2026 zaktualizowane przez: Bristol-Myers Squibb

Wieloośrodkowe, jednoramienne, otwarte badanie fazy 1/2 w celu oceny skuteczności i bezpieczeństwa stosowania fedratynibu u pacjentów z Japonii z DIPSS (Dynamic International Prognostic Scoring System) — pierwotne zwłóknienie szpiku pośredniego lub wysokiego ryzyka, po czerwienica prawdziwa zwłóknienie szpiku (post-PV MF) lub post-istotna nadpłytkowość mielofibroza (post-ET MF)

The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements.

This is a Phase 1/2 multicenter, single arm, open-label study in Japanese subjects with DIPSS intermediate or high-risk PMF, post-PV or post-ET MF. The study consists of 2 parts: Phase 1 part to determine safety and tolerability and a RP2D. The Phase 1 portion of the study will explore one or more drug doses for fedratinib (300 mg and 400 mg) using a mTPI-2 design. Following completion of dose escalation and determination of MTD and/or a RP2D, the study will progress into the Phase 2 part to further evaluate the efficacy and safety.

The study will consist of 3 periods: a Screening Period, a Treatment Period including a 30-day follow-up after last dose visit and a survival follow-up period.

Przegląd badań

Status

Zakończony

Interwencja / Leczenie

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

31

Faza

  • Faza 2
  • Faza 1

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

      • Aomori, Japonia, 030-8553
        • Local Institution - 002
      • Bunkyō City, Japonia, 113-8677
        • Local Institution - 004
      • Fukuoka, Japonia, 812-8582
        • Local Institution - 015
      • Hitachi, Ibaraki, Japonia, 317-0077
        • Local Institution - 018
      • Isehara City, Kanagawa, Japonia, 259-1193
        • Local Institution - 005
      • Kamogawa, Japonia, 296-8602
        • Local Institution - 010
      • Kitakyushu, Japonia, 806-8501
        • Local Institution - 017
      • Kumamoto, Japonia, 8628655
        • Local Institution - 020
      • Maebashi, Japonia, 371-8511
        • Local Institution - 013
      • Miyazaki, Japonia, 889-1692
        • Local Institution - 012
      • Nagasaki, Japonia, 8528511
        • Local Institution - 009
      • Osaka, Japonia, 545-8586
        • Local Institution - 016
      • Sapporo, Japonia, 003-0006
        • Local Institution - 014
      • Shinagawa-ku, Tokyo, Japonia, 141-8625
        • Local Institution - 007
      • Shinjuku, Japonia, 162-8666
        • Local Institution - 008
      • Shinjyuku-ku, Japonia, 160-0023
        • Local Institution - 003
      • Takamatsu, Japonia, 760-0017
        • Local Institution - 019
      • Ōsaka-sayama, Japonia, 589-8511
        • Local Institution - 011
    • Nagano
      • Suwa, Nagano, Japonia, 392-8510
        • Local Institution - 021
    • Tokyo
      • Bunkyo-ku, Tokyo, Japonia, 113-8431
        • Local Institution - 001
    • Yamanashi
      • Chūō, Yamanashi, Japonia, 409-3898
        • Local Institution - 006

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

20 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

Subjects must satisfy the following criteria to be enrolled in the study:

  1. Subject is ≥ 20 years of age at the time of signing the informed consent form (ICF)

  2. Subject has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0, 1 or 2

  3. Subject has diagnosis of Primary myelofibrosis (PMF) according to the 2016 World Health Organization (WHO) criteria, or diagnosis of post-ET or post- Polycythemia vera (PV) Myelofibrosis (MF) according to the IWG-MRT 2007 criteria, confirmed by the most recent local pathology report

  4. Subject has a Dynamic International Prognostic Scoring System (DIPSS) Risk score of Intermediate-1 with symptom(s), Intermediate-2 or High

  5. Subject has a measurable splenomegaly during the screening period as demonstrated by spleen volume of ≥ 450 cm3 by magnetic resonance imaging (MRI) or computed tomography (CT) scan or by palpable spleen measuring ≥ 5 cm below the left costal margin.

  6. Subject must meet at least one of the following criteria of (a or b).

    Note: reason to discontinue ruxolitinib treatment (lack of efficacy and/or intolerability, etc) and physician decision as to the study participation as being appropriate should be recorded in the case report form:

    1. Previously received ruxolitinib treatment for PMF or post-PV MF or post-ET MF for at least 14 days (exposure of < 14 days is allowed for subjects who discontinued ruxolitinib due to intolerability or allergy).
    2. Never received ruxolitinib treatment and is expected to derive clinical benefit from this study participation based on the clinical judgement of the Investigator Only those subjects who previously received ruxolitinib treatment are eligible for the Phase 1 part of the study to avoid overestimating tolerability of fedratinib.
  7. Subject must have treatment-related toxicities from prior therapy resolved to Grade 1 or pretreatment baseline before start of last therapy prior to starting the fedratinib treatment.

  8. Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.

  9. Subject is willing and able to adhere to the study visit schedule and other protocol requirements.

  10. A female of childbearing potential (FCBP) must:

    1. Have 2 negative pregnancy tests as verified by the Investigator during screening prior to starting fedratinib treatment. She must agree to ongoing pregnancy testing during the course of the study, and after end of fedratinib treatment. This applies even if the subject practices true abstinence* from heterosexual contact.
    2. Either commit to true abstinence* from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use and be able to comply with highly effective contraception** without interruption, -14 days prior to starting investigational product, during the fedratinib treatment (including dose interruptions), and for 30 days after discontinuation of fedratinib treatment.
    3. If breastfeeding, agree to stop breastfeeding prior to the participation in the study and not to resume breastfeeding for at least 30 days after treatment discontinuation of the fedratinib treatment.

    Note: A female of childbearing potential (FCBP) is a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy, or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy or amenorrhea due to other medical reasons does not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months).

  11. A male subject must:

Practice true abstinence (which must be reviewed on a monthly basis) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 30 days following fedratinib discontinuation, or longer if required by local regulations, even if he has undergone a successful vasectomy.

True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception).

Agreement to use highly effective methods of contraception that alone or in combination resulting in a failure rate of a Pearl index of less than 1% per year when used consistently and correctly throughout the course of the study. Such methods include combined (estrogen and progestogen containing) hormonal contraception (oral), progestogen-only hormonal contraception associated with inhibition of ovulation (oral), placement of an intrauterine device, placement of an intrauterine hormone-releasing system, bilateral tubal occlusion, and vasectomized partner.

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

  1. Any of the following laboratory abnormalities:

    1. Platelets < 50 x 109/L (without platelet transfusion)
    2. Absolute neutrophil count (ANC) < 1.0 x 109/L
    3. White blood count (WBC) > 100 x 109/L
    4. Myeloblasts ≥ 5 % in peripheral blood
    5. Estimated creatinine clearance < 30 mL/min (as estimated by Cockcroft-Gault formula)
    6. Serum amylase or lipase > 1.5 x upper limit of normal
    7. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x upper limit of normal (ULN)
    8. Total bilirubin > 1.5 x ULN, subject's total bilirubin between 1.5 - 3.0 x ULN are eligible if the direct bilirubin fraction is < 25% of the total bilirubin.
  2. Subject is pregnant or breastfeeding female.

  3. Subject with previous splenectomy

  4. Subject with previous or planned hematopoietic Stem-cell transplantation (SCT)

  5. Subject with prior history of Encephalopathy, including Wernicke encephalopathy (WE)

  6. Subject with signs or symptoms of encephalopathy, including WE (eg, severe ataxia, ocular paralysis or cerebellar signs) without documented exclusion of WE by thiamine level and brain MRI

  7. Subject with thiamine deficiency, defined as thiamine levels in whole blood below normal range according to institutional standard and not demonstrated to be corrected prior to starting the fedratinib treatment

  8. Subject with concomitant treatment with or use of pharmaceutical, herbal agents or food known to be strong or moderate inducers of Cytochrome P450 (CYP) 3A4, and dual CYP2C19 and CYP3A4 inhibitors

  9. Subject on any chemotherapy, immunomodulatory drug therapy (eg, thalidomide, interferon-alpha), anagrelide, immunosuppressive therapy, systemic corticosteroids > 10 mg/day prednisone or equivalent. Subjects who have had prior exposure to hydroxyurea (eg, Hydrea) in the past may be enrolled into the study as long as it has not been administered within 14 days prior to starting the fedratinib treatment.

  10. Subject on treatment with myeloid growth factor (eg, granulocyte-colony stimulating factor [G-CSF]) within 14 days prior to starting the fedratinib treatment

  11. Subject with previous exposure to JAK inhibitor(s) other than ruxolitinib treatment

  12. Subject has received ruxolitinib within 14 days prior to starting the fedratinib treatment

  13. Subject on treatment with aspirin with doses > 150 mg daily

  14. Subject with major surgery within 28 days prior to starting the fedratinib treatment

  15. Subject with diagnosis of chronic liver disease (eg, chronic alcoholic liver disease, autoimmune hepatitis, sclerosing cholangitis, primary biliary cirrhosis, hemochromatosis, non-alcoholic steatohepatitis)

  16. Subject with prior malignancy other than the disease under study unless the subject has not required treatment for the malignancy for at least 3 years prior to the start of fedratinib treatment. However, subject with the following history/concurrent conditions provided successfully treated may enroll: non-invasive skin cancer, in situ cervical cancer, carcinoma in situ of the breast, incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis [TNM] clinical staging system), or is free of disease and on hormonal treatment only

  17. Subject with uncontrolled congestive heart failure (New York Heart Association Classification 3 or 4)

  18. Seropositive for and with evidence of active viral infection with hepatitis B virus (HBV)

    1. Subject who are hepatitis B surface antigen (HBsAg) negative but HB core anti-body (HBcAb) positive or HBsAb positive are eligible in case HBV viral deoxyribonucleoside (DNA) negative
    2. Subject who had HBsAg positive but show non-detectable viral DNA for at least 6 months prior to starting the fedratinib treatment where appropriate anti-viral treatment should have been given/considered to prevent HBV reactivation based on the standard practice are eligible
    3. Subject who are seropositive because of hepatitis B virus vaccine are eligible
  19. Seropositive for and with active viral infection with hepatitis C virus (HCV)

    • Subject who had hepatitis C but show no detectable HCV viral ribonucleotide (RNA) for at least 6 months prior to starting the fedratinib treatment are eligible.

  20. Evidence of human immunodeficiency virus (HIV) infection.

  21. Subject with serious active infection

    • Additionally, subject with history of active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 4 weeks prior to screening, unless the subject has adequately recovered from coronavirus disease (COVID) symptoms and related complications as per investigator's discretion, and following a discussion with the Medical Monitor.

  22. Subject with presence of any significant gastric or other disorder that would inhibit absorption of oral medication

  23. Subject is unable to swallow capsule

  24. Subject with any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study

  25. Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if the subject were to participate in the study

  26. Subject has any condition that confounds the ability to interpret data from the study

  27. Subject with participation in any study of an investigational agent (drug, biologic, device) within 30 days prior to starting the fedratinib treatment

  28. Subject with a life expectancy of less than 6 months from the planned first dose of fedratinib.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Nie dotyczy
  • Model interwencyjny: Zadanie dla jednej grupy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Fedratinib Administration

The fedratinib dose is 300 or 400 mg/day PO (3 or 4 x 100 mg capsules) to be self-administered orally once daily continuously on an outpatient basis, preferably together with food during an evening meal, the same time each day.

Specified dose on specified days

Inne nazwy:
  • BMS-847943

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Maximum Tolerated Dose (MTD)
Ramy czasowe: Up to Cycle 1 (each cycle is 28 days)

is the highest dose that causes DLTs in not more than 33% of the subjects treated with fedratinib in the first cycle with at least 3 evaluable subjects treated at this dose.

Up to Cycle 1 (each cycle is 28 days)
Recommended Phase 2 dose (RP2D)
Ramy czasowe: Up to Cycle 1 (each cycle is 28 days)

is a recommended Phase 2 dose that is determined as safe and tolerable by the Safety Review Committee based on the data from the first cycle with at least 3 evaluable subjects treated at each dose of the Phase 1 part.

Up to Cycle 1 (each cycle is 28 days)
Response Rate (RR)
Ramy czasowe: Up to Cycle 6 (each cycle is 28 days)

Proportion of subjects who have ≥ 35% SVR at end of Cycle 6 from baseline

Up to Cycle 6 (each cycle is 28 days)

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Adverse Events (AEs)
Ramy czasowe: From ICF signature up until 30 days after last dose of IP

An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE.

From ICF signature up until 30 days after last dose of IP
Pharmacokinetics - Cmax
Ramy czasowe: Up to Cycle 1 (each cycle is 28 days)

Peak (maximum) plasma concentration of the drug

Up to Cycle 1 (each cycle is 28 days)
Pharmacokinetics - AUC
Ramy czasowe: Up to Cycle 1 (each cycle is 28 days)

Area under the plasma concentration curve

Up to Cycle 1 (each cycle is 28 days)
Pharmacokinetics - Tmax
Ramy czasowe: Up to Cycle 1 (each cycle is 28 days)

Time to maximum plasma concentration

Up to Cycle 1 (each cycle is 28 days)
Symptom response rate (SRR)
Ramy czasowe: Up to Cycle 6 (each cycle is 28 days)

Proportion of subjects with ≥ 50% reduction in total symptom scores measured by MFSAF version 2.0 (Appendix C) at end of Cycle 6

Up to Cycle 6 (each cycle is 28 days)
Spleen volume response rate 25 (RR25)
Ramy czasowe: Up to Cycle 6 (each cycle is 28 days)

Proportion of subjects who have ≥ 25% reduction in spleen volume at the end of Cycle 6

Up to Cycle 6 (each cycle is 28 days)
Spleen Response Rate by Palpation (RRP)
Ramy czasowe: Up to Cycle 6 (each cycle is 28 days)

Proportion of subjects who have ≥ 50% reduction in spleen size by palpation at end of Cycle 6

Up to Cycle 6 (each cycle is 28 days)
Duration of spleen volume response (DR)
Ramy czasowe: Up to 4 years

Duration of ≥ 35% SVR by MRI/CT

Up to 4 years
Duration of spleen response by palpation (DRP)
Ramy czasowe: Up to 4 years

Time from the first documented palpable spleen response, according to the IWGMRT 2013 to the time of the first documented loss of response according to the IWG-MRT 2013.

Up to 4 years
Duration of symptoms response (DSR)
Ramy czasowe: Up to 4 years

Duration of ≥ 50% reduction in total symptom scores measured by MFSAF version 2.0

Up to 4 years
Spleen and Disease Progression Free Survival (SDPFS)
Ramy czasowe: Up to 4 years

Time from the start of fedratinib treatment to death due to any reason or disease progression (modified IWGMRT 2013 including ≥ 25% increase in spleen volume by MRI/CT)

Up to 4 years
Gastrointestinal adverse events
Ramy czasowe: From ICF signature to the 30-day follow-up after last dose of IP

Incidence of subjects with Grade 3 or higher Gastrointestinal events (nausea, diarrhea, or vomiting) according to CTCAE v5.0

From ICF signature to the 30-day follow-up after last dose of IP
Wernicke encephalopathy (WE) events
Ramy czasowe: From ICF signature to the 30-day follow-up after last dose of IP

Occurrence of confirmed Wernicke encephalopathy events

From ICF signature to the 30-day follow-up after last dose of IP
Overall Survival (OS)
Ramy czasowe: Up to 4 years

Time from the start of fedratinib treatment to death due to any reason

Up to 4 years

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Dyrektor Studium: Bristol-Myers Squibb, Bristol-Myers Squibb
  • Dyrektor Studium: Bristol Myers Squibb, Bristol-Myers Squibb

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

12 października 2020

Zakończenie podstawowe (Rzeczywisty)

5 października 2023

Ukończenie studiów (Rzeczywisty)

16 października 2026

Daty rejestracji na studia

Pierwszy przesłany

16 czerwca 2020

Pierwszy przesłany, który spełnia kryteria kontroli jakości

23 czerwca 2020

Pierwszy wysłany (Rzeczywisty)

25 czerwca 2020

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

12 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

8 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Ramy czasowe udostępniania IPD

See Plan Description

Kryteria dostępu do udostępniania IPD

See Plan Description

Typ informacji pomocniczych dotyczących udostępniania IPD

  • PROTOKÓŁ BADANIA
  • SOK ROŚLINNY
  • CSR

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj